ÂÜÀòÂÒÂ×

Hideki Miyatake Ondozabal is a Senior Director of Therapeutic Modalities at Bayer, having joined in August 2024. Prior to this role, Hideki served as a Visiting Scientist and Project Leader at Vividion Therapeutics, Inc., focusing on chemoproteomic-enabled covalent drug discovery for precision molecular oncology and neurodegenerative diseases from June 2022 to July 2024. Hideki's experience at Bayer Pharmaceuticals includes roles as Project Portfolio Lead overseeing Immuno-Oncology and Women’s Health indications, and as Head of Laboratory for both Gynecological Therapy and Hematology & Cardiology from January 2015 to May 2022. Academic background includes a post-doctoral associate position at the University of Basel, where Hideki worked on the total synthesis of complex natural products with Prof. Karl Gademann from June 2012 to November 2014, and a PhD in organic synthesis with Prof. Anthony G. M. Barrett at Imperial College London, completed in 2012. Additionally, Hideki holds a Master's degree in Organic Chemistry from The University of Manchester.